31 results about "Genus Serratia" patented technology

The invention provides methods of producing secondary metabolites and under recombinant products oxygen-limited or anaerobic culture conditions. The methods include providing a porous substrate having a first side and a second side and which has a biofilm of microorganisms attached to the first side thereof, and causing a nutrient solution to flow through the biofilm and the substrate in a direction from the first side thereof to the second side thereof under oxygen-limited or anaerobic culture conditions. The microorganisms include Clostridium sp., Bacillus sp., Pseudomonas sp. Vibrio sp., Serratia sp., Rhodopseudomonas sp., Anaeromyxobacter sp., Desulphovibrio sp., and Candida sp., Lactococcus lactis, Escherichia coli, Bacillus subtillus, Pichia sp., Candida sp., Hansenula polymorpha and Saccharomyces cerevisiae.

The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

The purpose of the present invention is to provide an injectable vaccine composition that is safe and useful as a prophylactic or therapeutic agent for cancer or infectious diseases and can safely and effectively induce a systemic immune response. An injectable vaccine composition that is to be administered by injection to human or animals, characterized by comprising at least one kind of antigen and a lipopolysaccharide or a salt thereof as an immunostimulator, said lipopolysaccharide being derived from at least one kind of gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas and Enterobacter.

The present invention discloses an application of serratia marcescens vaccine in preparation of medicine for curing pulmonary fibrosis. The animal tests show that said serratia marcescens vaccine has obvious action for curing pulmonary fibrosis. As compared with hormone said serratia marcescens has incomparable safety.

The purpose of the present invention is to provide a mucosal vaccine composition that is effective and safe as a prophylactic or therapeutic drug for infections and cancer, which effectively induces a systemic immune response and mucosal immune response, and which can be administered to the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa. The present invention is a mucosal vaccine composition administered to at least one mucous membrane of a person or animal, said mucous membrane being selected from the group consisting of oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, and rectal mucosa. The mucosal vaccine composition is characterized by including at least one type of antigen, and, as an immunostimulant, a lipopolysaccharide or a salt thereof derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter.

The invention discloses a serratia strain which is rich in phosphorus, degrades organic phosphorus and inhibits plant pathogenic fungi, and belongs to the technical field of microorganisms. the strain Serratia sp.MEW06 is preserved in the China Type Culture Collection Center, and the preservation number is CCTCC NO.M 2015779. The Serratia bacterium of the present invention has a short-term and high-efficiency phosphorus-enriching ability, which can be used to prepare biological fertilizers, and also has the effect on pathogenic fungi of crops. Disease suppression, can be applied to microbial control, at the same time, the bacterial strain has a good degradation effect on organophosphorus pesticide glyphosate and dimethoate, can effectively remove organophosphorus pesticide pollution, Serratia of the present invention has a wide range of applications scope.

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt, derived from at least one gram-negative bacterium such as Serratia, Lelercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant / the total mass of the antigen, of 0.002 to 500.

A strain of Serratia marcescens (Serratia marcescens) T861 resistant to canker sores of citrus was preserved in the China Center for Type Culture Collection on April 10, 2015, with the preservation number CCTCC? NO: M2015222. The fermented liquid of the bacterial strain T861 of the present invention has inhibitory effect on X. citrus bacteria, and the in vitro inhibition rate of the aseptic fermented liquid on X. citrus bacteria is more than 86.7% as measured by the acupuncture method.